Long-term study of azetukalner for depression
Treatments studied
Part of Mental health clinical trials.
This study is for people who already completed a previous trial of azetukalner for major depressive disorder. It tests the long-term safety and effects of continuing the medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already finished a phase 3 study of azetukalner for major depression.
- You need to understand the study and sign a consent form.
- You must agree to use birth control as required.
- Men cannot donate sperm for 3 months after the last dose, and women cannot donate eggs for the same period.
- You cannot be pregnant, breastfeeding, or planning pregnancy within 3 months of the last dose.
- You must not have any medical issues or side effects from the previous study that would make this study unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medication called Azetukalner against a placebo to see if it helps reduce symptoms of major depressive disorder. You may qualify if you are currently in a depressive episode that started in adulthood and have not tried or failed only a few antidepressants.
This study tests a new oral medication called Zelquistinel (taken as a tablet) against a placebo for treating major depressive disorder. Researchers want to see if it can reduce depression symptoms, especially when other antidepressants haven't been tried or haven't worked.
This long-term study is for people who already completed an earlier trial of the experimental drug CYB003 for major depression and who stayed on their regular antidepressant. It looks at the safety and effects of taking CYB003 again over many months.
This study tests an experimental oral pill called azetukalner against a placebo to see if it safely reduces symptoms of major depressive disorder. It is for adults who are currently in a depressive episode lasting 6 weeks to 2 years and have not already tried multiple antidepressants that failed.
This Phase 2 trial tests whether an NMDA-targeted treatment can improve symptoms of major depressive disorder (MDD). You may be able to join if your depression diagnosis and symptom score fit, and you meet several safety and study-following requirements.
This Phase 3 study tests a stronger medication approach after your first current treatment hasn’t worked well enough. It targets people with schizophrenia, major depressive disorder, or bipolar depression who still have significant symptoms and life impact.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.